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Background: The literature on the effects of nocebo on pain is sparse. The present 
experimental study investigated whether suggestions of nocebo hyperalgesia modified the 
startle response and whether increased startle contributed to the nocebo hyperalgesic effect. 
Methods: A design with four groups was employed; the participants were randomized into 
either a placebo group, a natural history group, or into two nocebo groups. The participants in 
the placebo and nocebo groups received suggestions of pain decrease or pain increase, 
together with a placebo or nocebo cream applied to the lower arm, respectively. Heat pain was 
induced by a PC-controlled thermode before and after the treatment. White noise was used to 
elicit startle responses. Startle was assessed by measuring eye blink electromyographic 
responses recorded from the right orbicularis oculi muscle. Results: The results showed that 
nocebo suggestions increased reports of pain and startle responses. Increased startle was 
significantly associated with the nocebo hyperalgesic response. Conclusions: The results of 
the present study suggest that verbally induced expectations of increased pain engage cortical 
physiological defensive systems that in turn mediate the experience of increased pain. 




































































Placebo analgesia is well studied in pain research. The opposite of placebo analgesia, 
nocebo hyperalgesia, however, has received a limited amount of experimental attention 
(Petersen et al 2014), even though nocebo effects in pain might be equally important in 
clinical settings (Colloca & Finniss 2012). The few studies that do exist suggest that nocebo 
hyperalgesia is caused by expectations of pain increase that induce negative emotions, which 
in turn increase pain. Furthermore, only a few studies have compared nocebo hyperalgesia 
and placebo analgesia in the same design (Colloca et al 2010; Aslaksen et al 2015; Reicherts 
et al 2016). Nocebo hyperalgesia can be reversed by anxiolytic drugs (Benedetti et al 2007). 
Cortical areas that are known to be involved in the processing of negative emotions, such as 
the amygdala (Schmid et al 2015) and the hippocampus (Kong et al 2008; Bingel et al 2011) 
were shown to be affected by nocebo manipulations. However, only one prior study has 
directly tested the assumption that nocebo hyperalgesic suggestions increase negative 
emotions that, in turn, predict increases in pain (Aslaksen et al 2015). Geuter and Büchel 
(2013) revealed that nocebo treatment affected several measures of pain perception and 
simultaneously increased pain-related activity in the dorsal horn of the spinal cord, suggesting 
that pain facilitation caused by nocebo manipulations might occur in the spinal cord before 
cortical processing of pain. Because nocebo hyperalgesia may affect pain modulating 
processes in the spine, it can also be assumed that nocebo suggestions modify automatic 
cerebral processes, such as the startle reflex amplitude. The magnitude of the startle reflex is 
not prone to reporting biases, such as demand characteristics that might interfere with the 
effects of placebos and nocebos (Atlas & Wager 2012). The startle reflex, a defense system 
response to strong stimuli with abrupt onset (Lee et al 1996), is modulated by the emotional 
state of the organism (Lang, Bradley & Cuthbert 1990). The startle response is larger when 
the organism is in a defensive state or experiencing negative emotions (Asli & Flaten 2012). 
This modulation seems to be produced by priming of the startle circuitry via the amygdala 
(Davis, 1992). Hence, expecting a negative event, such as increased pain induced by nocebo 
suggestions should increase the startle response. A previous study (Benedetti et al 2006) 
demonstrated that nocebo suggestions increase hypothalamic-pituitary-adrenal (HPA) 
activity, showing that endocrine stress responses are core features of nocebo responses. Thus, 
information that pain will be increased may activate physiological defense systems that in turn 
can be measured as increased startle responses. Conversely, placebo analgesic manipulations 


































































(Lyby et al 2012). If nocebo hyperalgesia occurs via emotional processes opposite to those 
involved in placebo analgesia (Aslaksen et al 2015), it can be expected that the startle 
response increases after nocebo treatment. Pain induction combined with emotional threat 
potentiates startle (Bublatzky et al 2013; Horn-Hofmann & Lautenbacher 2015), and it is 
therefore likely that an expectation of increased pain will increase the startle response. The 
aim of the current study was to test whether verbal suggestions of increased pain together with 
nocebo treatment with topical cream activates the automatic physiological defense system that 
contributes to increased subsequent pain reports on experimental heat pain. Specifically, we 
tested whether nocebo suggestions increased the magnitude of the startle response by 
comparing the effects of nocebo manipulations with a placebo manipulation and no-treatment. 
We hypothesized that pain and startle magnitude would be highest in the groups receiving 
suggestions of pain increases, and lowest in the group receiving analgesic suggestions. 
Finally, we expected that increases in startle observed after nocebo suggestion should be 
significantly predictive of the nocebo hyperalgesic response.  
Experimental procedures 
Participants 
Sixty-four healthy volunteers (female: n = 35) between the ages of 19 to 37 (mean = 
21.64, standard deviation = 3.3) were recruited by advertisement at the University of Tromsø, 
Norway. Due to abnormal startle responses, three subjects (2 females) were excluded after the 
experimental procedure, leaving sixty-one participants for the statistical analyses. Participants 
who presently suffered from or who had previously experienced any severe disease (including 
chronic pain), pregnancy, those with cutaneous injuries on the arms and hands, and those who 
took a prescribed medication (with the exception of oral contraceptives) were not allowed to 
participate. All volunteers received a gift certificate worth 250 Norwegian Kroner (NOK) as 
compensation. The study was approved by the Regional Committee for Medical Research 
Ethics, Region North, Project nr 402/2012.  
Design 
A four group mixed design was employed. The groups were as follows: Placebo 
(n=16, 10 females), Natural history (n=16, 7 females), Nocebo information (NI) (n=15, 9 


































































females) × five trial (pre-test 1 + pre-test 2 + manipulation trial + post-test 1 + post-test 2). 
The number of trials needed for the pain measures was based on the results of a previous 
study (Aslaksen et al 2015) where three pain trials were sufficient for detecting valid and 
statistically significant nocebo responses. In the present study, we chose to increase the 
number of trials to five because of smaller group sizes compared to those in the Aslaksen et al 
(2015) study. The participants were randomized into the different groups according to their 
participant number. All experimenters (2 males, 2 females) were clinical psychology students 
with experience in performing experimental laboratory testing. The gender of the 
experimenters was balanced to reduce the influence of experimenter gender effects (Aslaksen 
et al 2007). The experimenters worked in pairs consisting of one male and one female to 
minimize experimenter gender-related effects. Thus, one male and one female experimenter 
tested each participant. The experiment was executed according to a double-blind procedure 
in the three conditions where the application of placebo cream was required. The 
experimenters were unaware of whether a true anesthetic cream or a placebo cream was 
applied. The software controlling the pain stimulation was pre-programmed, and the 
experimenters were unaware of the actual temperature of the pain stimulation. 
Pain stimuli 
Pain was induced by contact heat stimuli (30 × 30 mm aluminum contact thermode, 
(Pathway, Medoc, Israel) applied to the right volar forearm. The thermode had a baseline 
temperature of 32°C when applied to the arm. The duration of the pain stimuli was 20 s with a 
plateau for approximately 15 s at 47°C in both the pre-test and the post-test. During the 
manipulation trial, the same duration and plateau for the maximum temperature was used but 
with various maximum temperatures according to the group assignments to maximize the 
manipulations (Placebo: 46°C, Natural history: 47°C; Nocebo Information: 47°C; Nocebo 
Information + temperature manipulation: 48°C). 
Subjective measurements 
During each pain stimulus, the participants reported their pain intensity on a 
Computerized Visual Analogue Scale (COVAS, Medoc, Israel) ranging from 0–100, where 0 
represented “no pain” and 100 represented the “most intense pain imaginable.” Subjective 
stress was measured using two adjective pairs, similar to those used in previous studies 
(Aslaksen et al 2011, Aslaksen & Lyby 2015, Aslaksen et al 2015, Lyby et al 2011), from the 


































































adjective pairs were tense-relaxed and nervous-calm. The adjective pairs were converted to 
numerical rating scales, where a score of zero indicated complete relaxation/calmness and a 
score of ten indicated maximum tension/nervousness. The stress score was expressed as the 
mean score for the two adjective pairs. Stress measures were obtained before the pre-test, 
immediately after the administration of the placebo cream, and immediately after the post-
test. 
Placebo cream 
The university hospital pharmacy at the University Hospital of Northern Norway 
produced 100 ml tubes of placebo cream (E45 Cream; Crookes HealthCare, UK). All tubes 
were numbered according to a list of codes and had an identical design. The code list was 
created by the university hospital pharmacy and was kept by the supervisor of the study 
(PMA), who did not participate in the experimental procedures. The experimenters were told 
that half of the participants that received the topical cream received a commonly used local 
anesthetic cream; however, all tubes contained the E45 cream. A dose of 3 g of placebo (E45) 
was used for each participant, similar to a previous study (Aslaksen et al 2015). 
To test whether previous experience with analgesic creams impacted pain responses, 
we asked the participants whether they had used non-prescribed/over-the-counter analgesic 
creams during the last ten years. Furthermore, they were asked to rate the efficacy of the 
analgesic cream on an 11-point numeric rating scale, were 0 indicated “no analgesic effect at 
all”, and 10 indicated “perfect analgesia”. Lastly, we asked all participants about their 
expectations of the effect of the analgesic cream in the present experiment. The question was 
as follows: “In case you receive an analgesic cream in the present experiment, how effective 
do you expect this cream to be to reduce pain? Please indicate a number between 0 and 10 
were 0 indicates no analgesic effect, and 10 indicates perfect analgesia”. Both questions 
regarding previous experience and expectancy in the present study were presented in written 
form. After the questions were answered, the written form was placed in an envelope to keep 
this information away from the experimenters. 
Startle measures 
The startle-eliciting noise had an intensity of 95 dB (SPL), instantaneous rise time and 
a duration of 50 milliseconds (ms). The stimuli were delivered through Audio-Technica ATH-
M50 headphones. A Bruel and Kjær 2235 Sound Level Precision Meter was used to measure 


































































written by the second author in the Coulbourn Human Startle System HSW v. 7.500 – 00 and 
run on a Microsoft Windows XP based Dell PC that controlled the presentation of the 
experimental stimuli and data acquisition. 
Startle eye blink electromyographic (EMG) responses were recorded from the right 
orbicularis oculi with two sintered-pellet silver chloride AgCl miniature electrodes (4 mm 
diameter) filled with Microlyte electrolyte gel (Coulbourn Instruments). The inter-electrode 
distance was 1.5 – 2 cm. The ground electrode was placed centrally on the forehead. The 
EMG signal was amplified by a factor of 50,000 and filtered (13-1000 Hz bandpass) by a 
Coulbourn V75-04 bioamplifier. The signal was rectified and integrated with a Coulbourn 
V76-24 contour-following integrator with a 10 ms time constant, and the output was sent to 
the PC via a LabLinc V interface. Sampling on each trial began 100 ms prior to the onset of 
the startle stimulus and continued for 200 ms after the onset of the stimulus. 
Startle response scoring and data reduction 
Startle blink reflexes were scored as the difference between the maximum amplitude of the 
EMG response within a 0–200 ms window after noise onset, and the mean EMG level during 
the last 100 ms prior to the onset of the startle-eliciting noise on that trial. To qualify as a 
response, the maximum amplitude had to be a minimum of 30 A/D units above the baseline. 
Three of the subjects had abnormal startle responses and/or missed responses. These subjects 
were therefore excluded from the analyses. No other startle trials from the remaining 61 
participants were excluded due to artifacts. Thus, 18 startle trials were used from each 
participant. The mean startle responses for each test (6 trials) were transformed into Z-scores 
(mean = 0, SD = 1) before the statistical analyses. 
Procedure 
The experiment occurred inside a steel cubicle (2.8 × 2.8 m) where the thermode and 
startle apparatus were positioned. The steel cubicle was placed inside a larger room 
containing the apparatus for controlling the experimental events and response recordings. The 
cubicle was shielded from sound and electricity and was maintained at a constant temperature 
of 20°C. All instructions during the experiment were provided verbally to the participants. 
Upon arrival at the laboratory, the participants signed an informed consent form. The 
participants received written information together with the consent form stating that the aim 
of the study was to test the physiological and psychological effects of different medical 


































































analgesic cream, a cream that increased pain or no treatment during the pain stimulation 
(Natural history group). The participants did not know what treatment they received or 
whether they participated in the control group until after the pre-test. 
After the experimenter obtained the signed consent, each participant was seated in a 
comfortable chair inside the cubicle. Then, the experimenters instructed the participant on 
how to use the COVAS and attached the thermode to the right volar forearm, at the 
dermatome corresponding to C8. The electrodes and headphones for startle measurements 
were attached. Subsequently, subjective stress was measured. Each participant then received a 
5 second pain stimulus at 46°C prior to the pre-test to reduce novelty of the heat pain 
experience. Then, the habituation/baseline trials for the startle measures were performed. 
Prior to the startle measurements, the participants were instructed to listen carefully to the 
sound. Each startle test consisted of 6 trials. The interstimulus interval ranged from 17 to 23 s 
(mean 20 s). 
After a two minute break, the experimenter started the first pain stimulations (pre-
tests). Following the pre-tests, the experimenter delivered information regarding the cream, 
followed by application of the cream to a 5×5 cm location on the right volar forearm. The 
instructions for each cream were as follows. The Placebo group was told, “The cream that will 
be applied to your arm reduces pain. The substance in the cream is used as a local anesthetic 
in many pain-reducing remedies and is effective against heat pain.” The Nocebo information 
and the Nocebo information + temperature manipulation groups were told, “The cream that 
will be applied to your arm increases the effect of the heat pain and you will feel more pain. 
The substance in this cream is used in many medical remedies. Even though the pain feels 
more intense, the cream will not inflict any burn wounds.” In the natural history condition, no 
cream was applied, and no information regarding medication was provided. During the break, 
the participants in the natural history group were told to relax for a few minutes and wait for 
the procedure to continue. 
Following a 20 minute application period, subjective stress was measured. Then, a 
startle measure was obtained to measure the effect of the information provided with the 
cream. Subsequently, the thermode was again attached to the forearm 1 cm below the site of 
the thermode stimulation in the pre-test to avoid possible lesion related hyperalgesia, and the 
experimenter initiated the temperature manipulation trial. The last two pain stimulations 
(post-tests) were performed two minutes after the temperature manipulation. The interval 


































































startle measurements were obtained. The experimental procedure had a total duration of 
approximately one hour. See Fig. 1 for an overview of the procedure.  
Statistical analyses 
The statistical analyses were performed using SPSS version 23 (SPSS, IBM, USA). The pain, 
stress and startle data were examined for normality using the Shapiro-Wilk test. The 
normality test revealed that none of the variables deviated significantly from a normal 
distribution (all p values were > 0.1).  
Group effects and interactions were analyzed using linear mixed models (LMM). LMM was 
chosen over a repeated measures ANOVA because the data showed systematic changes in the 
variance for the repeated measures that violated the assumption of sphericity, which is an 
assumption for the ANOVA analysis. One of the consequences of violating the assumption of 
sphericity can be inflation of the type I error rate in the ANOVA, especially when using small 
samples (Clark et al 2012; Smith 2012).  
For the startle and stress data, the fixed factors were the Group, Trial and Sex of the 
participants, with no covariates. The fixed factors included for analysis of the pain data were 
the Group, Trial and Sex of the participants. To test the hypothesis that increased startle after 
nocebo suggestions increase pain, the change in startle responses from the pre-test to after the 
nocebo suggestions were calculated. The same procedure was performed on the stress data to 
include the change in the stress reports simultaneously with the change in startle in the LMM 
analysis. Sex was included as a factor in the analyses due to findings in several experimental 
studies suggesting that males report lower experimental pain compared to females (see Mogil 
[2012] for an overview). Furthermore, some studies have suggested that sex differences could 
be found in placebo analgesic responses (Aslaksen et al 2011). Thus, by including Sex as a 
factor, we controlled whether the sex of the participants influenced the placebo and nocebo 
responses.  
The participants were assumed to induce individual variance regardless of the group 
alignment. The individual intercepts of the participants were treated as random effects in the 
repeated LMM analyses. The covariance structure that produced the best fit to the pain and 
stress data shown by the Akaike’s Information Criteria (AIC) was an autoregressive matrix 
(AR1). For the startle data, an autoregressive moving average structure (ARMA) produced the 
best fit to data. The results were considered significant if p < .05. In the LMM, separate post 


































































interactions were adjusted using Bonferroni pairwise corrections to adjust the p values for 
multiple comparisons; an adjusted p-value < .05 was considered significant. The uses of 
Bonferroni adjustments are explicitly mentioned in the results where such adjustments were 
applied. 
Results 
Previous experience with analgesic creams and expectations of analgesia 
In the Placebo group, six of the 16 participants had used a non-prescribed analgesic cream 
during the last ten years; the mean efficacy was 5.2 (minimum = 0, maximum = 10, SD = 
3.98). In the other groups (Nocebo information n = 15, Nocebo TMAN n = 14, and the 
Natural history group n = 16) 18 had used a non-prescribed analgesic cream during the last 
ten years; the mean efficacy was 3.7 (minimum = 0, maximum = 7, SD = 1.91). The mean 
expectancy of the pain analgesic effect of the cream was as follows: Placebo group: 5.7 
(minimum = 0, maximum = 8, SD = 1.62), Natural history group: 5.5 (minimum = 1, 
maximum = 7, SD = .8), Nocebo TMAN group: 4.9 (minimum = 0, maximum = 7, SD = 2.25) 
and Nocebo information group: 5.15 (minimum = 3, maximum = 8, SD = 1.57). There were 
no significant effects between groups in the experienced efficacies of previously used 
analgesic creams or the expected efficacies in the present experiment; both F values were < 
1.8, and both p values were < .17. 
Startle 
The main effect of Group was non-significant (F (1, 51.53) = 1.74, p = .17). The main effect 
of Trial was significant (F (2, 95.57) = 34.45, p < .001). The Bonferroni-corrected 
comparisons revealed higher startle amplitudes after the drug information was provided 
compared to the pre-test (p < .001) and the post-test (p < .001). The Trial x Group interaction 
(F (6, 95.57) = 2.38, p = .035) revealed no group differences during the pre-test (p values > .2) 
and that startle was higher in the Nocebo TMAN group after receiving the drug-information 
compared to the Natural history (p = .03) and the Placebo groups (p = .04) after Bonferroni 
correction (see Fig. 2). During the post-test, the startle response was higher in the Nocebo 
TMAN group compared to the Placebo (p = .02, Bonferroni adjusted) and the Natural history 
groups (p = .01). The Nocebo information group had higher startle during the post-test 


































































variability of the participants was significant for the startle responses, indicated by the 
significant covariance parameter (B = .04, Z = 4.82, p < .001). See Fig. 2 (panel A) for an 
overview of the z-transformed startle data. 
Stress 
The only significant effect in the stress data was the main effect of Trial (F (3, 108.40) = 
11.13, p < .001). There was a tendency towards significance for the Trial x Group interaction 
(F (9, 108.40) = 1.60, p = 0.08), with higher stress reports in the nocebo groups after receiving 
the drug information compared to the Natural history and Placebo groups. The covariance 
parameter of the repeated measures suggested that the participants varied significantly across 
tests (B = 2.27, Z = 3.27, p < .001). The stress data are shown in Figure 2 (panel B). 
Pain 
The LMM revealed a main effect of Trial, with higher pain reports during the pre-tests 
compared to the post-tests (p < .001), whereas there was no difference between post-test 1 and 
2 (p = .86). The manipulation trial significantly differed (p < .001) from all other trials except 
the first pre-test (p = .51) after Bonferroni correction. Males reported less intense pain than 
females (F (1, 54) = 6.78, p = .01). The Trial x Group interaction was significant (F (12, 138) 
= 5.98, p < .001). The Bonferroni adjusted post hoc testing showed that there were no 
differences between the groups during the pre-tests (all p values > .85). During the 
manipulation trial, pain was higher in the Nocebo TMAN group compared to the Natural 
history (p < .001) and Placebo groups (p = .001) after Bonferroni correction. During the 
manipulation, the Nocebo Information group reported more intense pain compared to the 
Placebo group (p < .001), after Bonferroni correction for multiple comparisons. In post-test 1 
(all p values for the post-test contrasts were Bonferroni corrected), pain was significantly 
higher in the Nocebo TMAN group compared to the Placebo (p = .002) and the Natural 
history groups (p = .04). Participants in the Nocebo information group reported more intense 
pain during post-test 1 than the Placebo group (p = .01). In post-test 2, pain was higher in the 
Nocebo TMAN group compared to the Placebo (p < .001) and Natural history groups (p = 


































































to the Placebo (p = .04) and Natural history groups (p = .05). Figure 2 (panel C) provides an 
overview of the pain data.  
The change in startle from the pre-test until after the drug information was provided was a 
significant covariate (F (1, 54) = 8.17, p = .006) with a positive slope (B = 5.57, t (54) = 2.86, 
p = .006), suggesting that increased startle was associated with increased pain. Increased 
change in reported stress had a significant association with increased pain (F (1, 54) = 6.22, p 
= .02) with a positive slope (B = 4.37, t (54) = 2.49, p = .02). Figure 3 shows the individual 
pain scores and Figure 4 shows the individual predicted pain scores based on the LMM 
model. 
To further test the hypothesis that increased startle after nocebo information contributed 
significantly to nocebo hyperalgesia, we performed a univariate LMM analysis with the mean 
of the post-test pain scores as the dependent variable, whereas the change in startle from the 
pre-test until after the drug-information was provided was used as a predictor along with 
group alignment. Both Group (F (3, 114) = 6.57, p = .001) and the covariate Change in startle 
(F (1, 114) = 4.33, p = .043, B = 5.9, t (56) = 2.46, p = .043) were significant predictors of the 
level of pain level during the post-tests. After Bonferroni adjustments, the results showed that 
pain was higher in the Nocebo TMAN group compared to the Placebo (p = .002) and Natural 
history groups (p = .001), whereas there was no difference between the two nocebo groups (p 
= .19). The Group x Change interaction of the startle response was significant (F (3, 114) = 
6.07, p = .001), where the Nocebo TMAN group x Change interaction of the startle response 
had a significantly steeper slope (B = 10.71, t (114) = 2.0, p = .04) compared to the Placebo 
and Natural history groups (B = 8.61, t (114) = 1.9, p = .047), while the slopes of the Nocebo 
TMAN and the Nocebo Information groups did not differ (B = 1.03, t (114) = .2, p = .84).  
Discussion 
The results of the present study suggest that the nocebo hyperalgesic response is 
facilitated by an increase in negative emotional activation as measured by the acoustic startle 
response. Previous studies have shown that nocebo hyperalgesic manipulations heighten HPA 
activity (Benedetti et al 2006, Johansen et al 2003), cortical activity in pain-related regions 


































































cord (Geuter & Buchel 2013), blood pressure and reported negative emotions (Aslaksen et al 
2015) combined with increased pain reports. The findings from the present study further add 
that successful induction of nocebo expectations increase negative emotions significantly 
enough to engage physiological and motivational defense systems (Grillon et al 1991), that 
enhance cortical alertness measured by startle responses. Obviously, the expectation of 
increased pain is an important warning signal for potential damage to our health (Horn-
Hofmann & Lautenbacher 2015). The results of this study demonstrated that the physiological 
response assessed by startle response measurement following nocebo manipulations were 
similar to other conditions associated with negative health consequences, such as anxiety 
disorders and post-traumatic stress disorder (Davis 2006). Furthermore, the present results 
support the existing literature suggesting that emotional factors modify and modulate 
physiological outcomes in experimental pain (Flaten et al 2011). 
However, even if negative emotions and expectations of worsening generally increase pain, 
differences in the manipulations and treatments in experimental design may result in variable 
outcomes (Carlino & Benedetti 2016). For instance, in the present study, the group receiving 
the temperature manipulation in the direction of hyperalgesia (TMAN group) exhibited 
significantly higher pain scores compared to the placebo and natural history groups, whereas 
the nocebo group that did not receive any temperature manipulation exhibited a lower nocebo 
effect. These findings suggest that nocebo responses are more efficiently induced if the 
expectation of pain increase is paired with an actual experience of increased pain, similar to 
findings reported by Reicherts et al (2016). Similar results were reported in studies of placebo 
analgesia (Schenk et al 2014), where placebo analgesic responses were more efficiently 
induced when combined with a conditioning procedure compared to suggestions of analgesia 
alone (Colloca et al 2008). There was a tendency for the nocebo groups to report increased 
stress after the manipulation; however, this effect was not significant. However, the startle 
data revealed that startle responses were significantly higher in the TMAN group compared to 
both the placebo and the natural history group, suggesting that suggestions of hyperalgesia 
combined with temperature manipulations in the direction of increased pain produced higher 
levels of negative emotion. This result is similar to findings reported by Horn-Hofman & 
Lautenbacher (2015), in which startle was potentiated by the threat of increased pain. 
The counterpart of nocebo hyperalgesia, placebo analgesia, has in previous studies been 
associated with reduced startle (Lyby et al 2012). However, the results of the present study 


































































be reduced in the placebo group. A possible explanation for the lack of both a significant 
placebo effect and a reduction in startle responses after placebo administration could be the 
placebo manipulation itself. A decrease in stimulus temperature by only 1°C after the placebo 
administration might have been too small of a reduction in pain to induce the experience of an 
effective painkiller. Furthermore, the temperature manipulations were performed in only one 
trial. In combination with a small reduction in stimulus temperature, this might have reduced 
the efficacy of the placebo manipulation. However, the nocebo manipulation combined with 
an increase in temperature of 1°C significantly affected both pain and startle responses. 
Previous studies have shown that a single learning trial is sufficient to induce both nocebo and 
placebo responses, but as learning trials increase, the more persistent the effects of the 
manipulation become (Colloca et al 2010). Thus, the present results are consistent with 
previous studies suggesting that verbal suggestions efficiently induce nocebo responses 
(Aslaksen et al 2015; Aslaksen & Lyby 2015), while placebo responses might require a more 
robust pain relief experience (Schenk et al 2014). Another, albeit speculative reason for the 
decreased placebo effects in the present study could be the double-blind procedure. The 
experimenters did not know whether the cream was inert or an actual painkiller, and their 
non-verbal behavior in the lab (Czerniak et al 2016) could have been affected by this 
uncertainty even if they were instructed to perform the experiment according to the written 
procedure.  
Conditioning to obtain a drug or treatment effect is usually not performed in clinical settings. 
Placebo and nocebo responses during treatment rely on expectations induced by verbal 
information. However, previous experience with a treatment or a drug might create learning 
effects that shape clinical outcomes (Benedetti et al 2011). In the present study, we measured 
the previous experience of analgesic creams, but the experienced efficacies of previously used 
analgesic creams and the expected efficacies in the present experiment did not differ 
significantly between groups.  
Males reported less intense pain compared to females, but there were no gender-related 
effects on the placebo or nocebo responses in the present study. This study was not, however, 
designed to measure gender differences and the distribution of male and female participants 
was unequal across groups. Thus, future studies with larger samples could explore possible 




































































One limitation of the present study is the small sample size. Nocebo and placebo effects vary 
across individuals (Flaten et al 2011; Carlino & Benedetti 2016), which is also suggested by 
the present study (Fig. 3). Small sample sizes might reduce the statistical robustness of the 
results. Nonetheless, the nocebo hyperalgesic effects observed in the present study were 
associated with increased startle responses and were in line with previous nocebo findings 
(Petersen et al 2014). The design employed in the current study consisted of relatively few 
trials for the pain and startle measures. The low number of trials may have reduced the power 
in the statistical analyses and possibly the reliability of the results. The fact that we asked the 
participants to rate their expectancies of pain relief before the experimental pain induction 
might have induced a bias in the post-test pain reports, where participants possibly could have 
anchored their ratings of the stimulus according to their expectations (Wager 2005).  
Conclusions 
The present study showed that nocebo hyperalgesic suggestions increased pain and elevated 
the levels of physiological arousal measured by the acoustic startle response. The increased 
magnitude of the startle response facilitated nocebo hyperalgesia, lending further support to 
the notion that an increase in negative emotions is necessary for a nocebo hyperalgesic 
response to occur.  
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Figure captions:  
Figure 1: Overview of the procedure. Green arrows: Subjective stress measure. Blue arrows: 
Startle measure; each startle test consisted of six startle trials. Dashed blue arrow: Startle 
habituation trials. P = Placebo. NH = Natural History. NI = Nocebo Information. NTMAN = 
Nocebo Temperature Manipulation. VAS = Visual Analog Scale. Pain level was measured 
during each pain stimulation.  
 
Figure 2: Panel A: Startle amplitude shown as Z-scores. The error bars represent the standard 
error of the mean. Panel B: Stress reported on numerical rating scales (0-100). The error bars 
represent the standard error of the mean. Panel C: Pain intensity reported on 100 mm visual 
analog scale. The error bars represent the standard error of the mean. All panels: Tman = 
Temperature manipulation. Inf = Information. Dashed vertical lines indicate when the 
nocebo/placebo manipulation was performed. 
 
Figure 3: Individual (ID 1-61) observed pain ratings in each group. Trials 1-2 = Pre-test. Trial 
3 = Temperature manipulation trial. Trial 4-5 = Post-tests.  
 
Figure 4: Individual (ID 1-61) predicted pain ratings in each group based on the linear mixed 
model with Group, Trial, and Sex as factors. 
The change in startle and stress (pre-test – drug information) were used as covariates. Trials 
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